08.05.2014 Views

Introduction - Uppsala Monitoring Centre

Introduction - Uppsala Monitoring Centre

Introduction - Uppsala Monitoring Centre

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

were fatal (Adams & Perry, 1958); UK in 1961, Canada in 1963, Sweden in<br />

1976, France in 1978 and Cyprus in 1980. Also withdrawn in Australia,<br />

Finland, Norway and Venezuela. HAI: banned in 9 countries.<br />

Availability: it is still available in some countries.<br />

Drug Lifespan: 5 years<br />

Delay in recognition: 5 years<br />

Delay by the company: four days<br />

Time span of withdrawals: 22 years<br />

Comment: the prompt action by Sandoz was excellent, but how was it still<br />

available in the UK, France, Canada, Sweden and Cyprus?<br />

1954 Diiododiethyltin/isolinoleic acid ester (Stalinon)<br />

Introduced in France.<br />

Use: treatment for staphylococcal infections.<br />

ADR: in 1954 triethyltin was shown to remarkably neurotoxic (Stoner et al., 1955)<br />

Cerebral oedema–headache, photophobia, vomiting and drowsiness due to<br />

raised intracranial pressure, and death occurring in 4-10 days (Le Quesne,<br />

1981).<br />

The intended dose used for toxicity testing should have been 50 mgm, but<br />

due to an error, they used only 3 mgm and the resulting absence of toxicity<br />

persuaded them to market a product containing 15 mgm per capsule. The<br />

responsible pharmacist was sent to prison for two years and the company<br />

held liable (D’Arcy & Griffin, 1986). There were no cases of poisoning for 6–<br />

7 months, which, it was suggested, was because organic tin salts have a<br />

delayed effect (HP, 1958). It was known that triethyltin was very neurotoxic<br />

and Stalinon contained a variable amount of triethyltin as an impurity (Le<br />

Quesne, 1981).<br />

Withdrawn: in France in 1957 because 110 patients died out of the 290 patients<br />

affected (Le Quesne, 1981)<br />

Availability: Nil<br />

Drug Lifespan: 3 years<br />

Delay in recognition: none<br />

Delay in regulatory action: 3 years<br />

Comment: an error by the pharmaceutical company plus a delayed ADR meant<br />

the drug remained on the market too long.<br />

1954 Glutethimide (Doriden)<br />

Use: hypnotic and sedative<br />

ADR: acute glaucoma, dependence and abuse (Sramek & Khajawall, 1982). The<br />

first case of dependence was reported in 1957(Rogers, 1958) and of addiction<br />

in 1960 (Cohen, 1960).

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!